Sign in or create an account to add this stock to your watchlist.
About Puma Biotechnology (NASDAQ:PBYI)
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500
Debt
Debt-to-Equity Ratio0.85
Current Ratio1.91
Quick Ratio1.87
Price-To-Earnings
Trailing P/E Ratio-6.61
Forward P/E Ratio-13.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.20 million
Price / Sales74.90
Cash FlowN/A
Price / CashN/A
Book Value$1.52 per share
Price / Book34.14
Profitability
EPS (Most Recent Fiscal Year)($7.85)
Net Income$-291,950,000.00
Net MarginsN/A
Return on Equity-314.05%
Return on Assets-141.14%
Miscellaneous
Employees318
Outstanding Shares37,810,000
Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology (NASDAQ:PBYI) released its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $0.61. The biopharmaceutical company earned $66.50 million during the quarter, compared to the consensus estimate of $67.33 million. During the same quarter last year, the firm posted ($1.16) EPS. View Puma Biotechnology's Earnings History.
When is Puma Biotechnology's next earnings date?
What price target have analysts set for PBYI?
9 equities research analysts have issued twelve-month target prices for Puma Biotechnology's shares. Their forecasts range from $68.00 to $146.00. On average, they expect Puma Biotechnology's share price to reach $102.2222 in the next year. View Analyst Ratings for Puma Biotechnology.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), GW Pharmaceuticals (GWPH), FibroGen (FGEN) and Hutchison China MediTech (HCM).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Mr. Alan H. Auerbach, Founder, Chairman, CEO, Pres & Sec. (Age 48)
- Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 70)
- Dr. Richard P. Bryce MBChB, MRCGP, MFPM, Chief Medical & Scientific Officer (Age 61)
- Mr. Steven Lo, Chief Commercial Officer (Age 51)
- Mr. Douglas Hunt, Sr. VP of Regulatory Affairs, Medical Writing & Project Management
Has Puma Biotechnology been receiving favorable news coverage?
Media stories about PBYI stock have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Puma Biotechnology earned a news impact score of 0.05 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Puma Biotechnology's major shareholders?
Puma Biotechnology's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.28%), Point72 Asset Management L.P. (3.39%), Redmile Group LLC (2.90%), Franklin Resources Inc. (2.27%), venBio Select Advisor LLC (2.18%) and Rock Springs Capital Management LP (1.09%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Which institutional investors are selling Puma Biotechnology stock?
PBYI stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, UBS Group AG, Millennium Management LLC, Eversept Partners LLC, BlackRock Inc., Sivik Global Healthcare LLC, California Public Employees Retirement System and Teacher Retirement System of Texas. Company insiders that have sold Puma Biotechnology company stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.
Which institutional investors are buying Puma Biotechnology stock?
PBYI stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., venBio Select Advisor LLC, Summit Trail Advisors LLC, Redmile Group LLC, BNP Paribas Arbitrage SA, PointState Capital LP, Federated Investors Inc. PA and Rock Springs Capital Management LP. View Insider Buying and Selling for Puma Biotechnology.
How do I buy shares of Puma Biotechnology?
Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of PBYI stock can currently be purchased for approximately $51.90.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $1.95 billion and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.
How can I contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]
MarketBeat Community Rating for Puma Biotechnology (PBYI)
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Puma Biotechnology (NASDAQ:PBYI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Puma Biotechnology in the last 12 months. Their average twelve-month price target is $102.2222, suggesting that the stock has a possible upside of 96.96%. The high price target for PBYI is $146.00 and the low price target for PBYI is $68.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.78 | 2.89 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $102.2222 | $103.1111 | $110.5556 | $130.6667 |
| Price Target Upside: | 96.96% upside | 60.61% upside | 21.62% upside | 26.86% upside |
Puma Biotechnology (NASDAQ:PBYI) Consensus Price Target History
Puma Biotechnology (NASDAQ:PBYI) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Puma Biotechnology (NASDAQ:PBYI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Puma Biotechnology (NASDAQ PBYI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 21.10%
Institutional Ownership Percentage: 97.95%
Puma Biotechnology (NASDAQ PBYI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/22/2018 | Alan H Auerbach | Insider | Sell | 10,692 | $92.75 | $991,683.00 | 4,155,931 |  |
| 1/22/2018 | Richard Paul Bryce | SVP | Sell | 1,860 | $92.75 | $172,515.00 | 25,379 | |
| 12/1/2017 | Charles R Eyler | Insider | Sell | 1,322 | $105.46 | $139,418.12 | | |
| 9/29/2017 | Richard Paul Bryce | SVP | Sell | 15,000 | $120.00 | $1,800,000.00 | 42,239 | |
| 9/7/2017 | Richard Paul Bryce | SVP | Sell | 15,000 | $100.09 | $1,501,350.00 | 28,239 | |
| 7/20/2017 | Alan H Auerbach | Insider | Sell | 13,175 | $94.73 | $1,248,067.75 | 4,170,623 | |
| 7/20/2017 | Richard Paul Bryce | SVP | Sell | 1,998 | $94.48 | $188,771.04 | 27,246 | |
| 7/3/2017 | Richard Paul Bryce | SVP | Sell | 5,000 | $87.10 | $435,500.00 | 34,237 | |
| 6/12/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 247,260 | $80.32 | $19,859,923.20 | | |
| 6/5/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 507,128 | $87.84 | $44,546,123.52 | | |
| 5/26/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 1,235,700 | $75.38 | $93,147,066.00 | | |
| 2/1/2017 | Robert Charnas | Insider | Sell | 3,008 | $31.83 | $95,744.64 | 28,461 | |
| 1/20/2017 | Alan H Auerbach | Insider | Sell | 10,202 | $33.24 | $339,114.48 | 4,179,798 | |
| 1/20/2017 | Richard Paul Bryce | SVP | Sell | 2,293 | $33.24 | $76,219.32 | 29,237 | |
| 7/6/2015 | Richard Paul Bryce | SVP | Sell | 3,000 | $110.03 | $330,090.00 | | |
| 11/8/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 22,549 | $38.92 | $877,607.08 | | |
| 11/5/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 280,700 | $39.60 | $11,115,720.00 | | |
| 10/9/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 140,900 | $40.44 | $5,697,996.00 | | |
| 12/18/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 29,560 | $19.00 | $561,640.00 | | |
| 12/12/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 30,400 | $19.00 | $577,600.00 | | |
| 12/11/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 140,040 | $18.98 | $2,657,959.20 | | |
| 10/24/2012 | Thomas Malley | Director | Buy | 10,000 | $16.00 | $160,000.00 | | |
| 10/18/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 610,000 | $16.00 | $9,760,000.00 | | |
(Data available from 1/1/2013 forward)
Puma Biotechnology (NASDAQ PBYI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Puma Biotechnology (PBYI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 17 at 12:43 PM |
 | Edited Transcript of PBYI earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 17 at 9:08 AM |
| Today's Research Reports on Trending Tickers: Puma Biotechnology and Amicus Therapeutics
finance.yahoo.com - May 16 at 9:08 AM |
| $47.45 Million in Sales Expected for Puma Biotechnology (PBYI) This Quarter
www.americanbankingnews.com - May 15 at 4:20 AM |
| -$1.18 EPS Expected for Puma Biotechnology (PBYI) This Quarter
www.americanbankingnews.com - May 13 at 8:56 AM |
| Stifel Nicolaus Trims Puma Biotechnology (PBYI) Target Price to $87.00
www.americanbankingnews.com - May 11 at 5:49 PM |
 | Puma Biotechnology (PBYI) PT Lowered to $87 at Stifel
www.streetinsider.com - May 11 at 9:37 AM |
| Today’s Research Reports on Stocks to Watch: Puma Biotechnology and Neovasc
finance.yahoo.com - May 11 at 9:37 AM |
| Here's Why Puma Biotechnology Inc. Is Sinking Today
finance.yahoo.com - May 10 at 5:08 PM |
| Puma Biotechnology (PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.61 EPS
www.americanbankingnews.com - May 10 at 4:46 PM |
 | Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down
www.zacks.com - May 10 at 9:07 AM |
| Puma Biotechnology (PBYI) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:51 PM |
 | Puma Bio Q1 Nerlynx sales $36M; non-GAAP earnings up 103%
seekingalpha.com - May 9 at 4:56 PM |
| Puma Biotechnology beats by $0.34, beats on revenue
seekingalpha.com - May 9 at 4:56 PM |
| Puma Biotechnology Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 4:56 PM |
| Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018
finance.yahoo.com - May 8 at 4:56 PM |
| Puma Biotechnology (PBYI) PT Set at $106.00 by Credit Suisse Group
www.americanbankingnews.com - May 8 at 2:28 PM |
| Puma Biotechnology (PBYI) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 7 at 1:13 PM |
| Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?
www.zacks.com - May 7 at 8:53 AM |
| Puma Biotechnology (PBYI) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 10:54 PM |
| Puma Biotechnology (PBYI) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 6:32 AM |
| Today's Research Reports on Trending Tickers: Neovasc and Puma Biotechnology
finance.yahoo.com - April 30 at 9:04 AM |
| Puma Biotechnology (PBYI) Given a $106.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - April 27 at 10:30 AM |
| Zacks: Brokerages Expect Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 Million
www.americanbankingnews.com - April 27 at 2:04 AM |
| Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$0.75 Per Share
www.americanbankingnews.com - April 25 at 7:16 PM |
| Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
finance.yahoo.com - April 25 at 4:59 PM |
| Puma Biotechnology Inc (PBYI) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 22 at 11:36 AM |
| Credit Suisse Group Reiterates "Outperform" Rating for Puma Biotechnology (PBYI)
www.americanbankingnews.com - April 17 at 6:29 PM |
| Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at Citigroup
www.americanbankingnews.com - April 17 at 5:27 PM |
| BidaskClub Upgrades Puma Biotechnology (PBYI) to "Strong-Buy"
www.americanbankingnews.com - April 14 at 9:51 PM |
 | The Market In 5 Minutes: Jobless Claims, Walmart-Flipkart, GE And More
www.benzinga.com - April 14 at 4:38 PM |
| Puma Biotechnology (PBYI) Stock Rating Reaffirmed by JPMorgan Chase
www.americanbankingnews.com - April 14 at 3:36 PM |
| Barclays Downgrades Puma Biotechnology (PBYI) to Equal Weight
www.americanbankingnews.com - April 12 at 11:15 AM |
| JPMorgan Chase Analysts Give Puma Biotechnology (PBYI) a $105.00 Price Target
www.americanbankingnews.com - April 11 at 1:19 PM |
| Puma Biotechnology (PBYI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 8:55 PM |
| Puma Biotechnology (PBYI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 3:25 PM |
| Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 Million
www.americanbankingnews.com - April 10 at 2:17 AM |
| Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Announce -$0.75 EPS
www.americanbankingnews.com - April 8 at 9:14 PM |
| Puma Biotechnology (PBYI) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - April 8 at 9:07 AM |
| 3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets Into Your Head, Myriad Gets Into Japan
seekingalpha.com - April 4 at 9:01 AM |
| Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
finance.yahoo.com - April 3 at 9:11 AM |
| Puma's Shares Fall This Year Post a Solid 2017: Here's Why
finance.yahoo.com - April 2 at 4:54 PM |
 | NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast ...
www.businesswire.com - April 2 at 9:26 AM |
| NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases
finance.yahoo.com - April 2 at 9:26 AM |
| Puma Biotechnology (PBYI) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - March 31 at 12:42 PM |
| Puma Biotechnology (PBYI) PT Set at $142.00 by Credit Suisse Group
www.americanbankingnews.com - March 28 at 3:48 PM |
| Puma Biotechnology Inc (PBYI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 11:54 AM |
| 3 Things In Biotech, March 26: A Focus On European Opinions
seekingalpha.com - March 27 at 9:18 AM |
 | Commit To Purchase Puma Biotechnology At $50, Earn 11.9% Annualized Using Options - Nasdaq
www.nasdaq.com - March 23 at 4:59 PM |
| Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - March 22 at 9:14 PM |
Puma Biotechnology (NASDAQ:PBYI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Puma Biotechnology (NASDAQ:PBYI) Income Statement, Balance Sheet and Cash Flow Statement
Puma Biotechnology (NASDAQ PBYI) Stock Chart for Saturday, May, 26, 2018
Loading chart…
